The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

A new era of B cell lymphoma treatment by using monoclonal antibody;Rituximab (anti-CD20 antibody)

단클론성 항체를 활용한 B 세포 악성 림프종 치료의 신기원: 리툭시맙

Cho, Seok-Goo
조석구

  • Published : 20060800
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol, 30:1-5, 2003
  2. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood, 101:391-398, 2003 https://doi.org/10.1182/blood-2002-06-1793
  3. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood, 90:2188- 2195, 1997
  4. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 16:2825-2833, 1998 https://doi.org/10.1200/JCO.1998.16.8.2825
  5. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38:1484-1493, 1976 https://doi.org/10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I
  6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr., Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328:1002-1006, 1993 https://doi.org/10.1056/NEJM199304083281404
  7. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin's lymphoma. N Engl J Med, 333:1540-1545, 1995 https://doi.org/10.1056/NEJM199512073332305
  8. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. European phase II study of rituximab (chimeric anti- CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol, 18:317-324, 2000 https://doi.org/10.1200/JCO.2000.18.2.317
  9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med, 346:235-242, 2002 https://doi.org/10.1056/NEJMoa011795
  10. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 7:379-391, 2006 https://doi.org/10.1016/S1470-2045(06)70664-7
  11. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 101:4279-4284, 2003 https://doi.org/10.1182/blood-2002-11-3442
  12. Marcus RC, Delaney CL, Easter SS Jr. Neurogenesis in the visual system of embryonic and adult zebrafish (Danio rerio). off. Vis Neurosci, 16:417-424, 1999 https://doi.org/10.1017/S095252389916303X
  13. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya- Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J and Moskowitz CH. Rituximab and ICE as secondline therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103:3684-3688, 2004 https://doi.org/10.1182/blood-2003-11-3911
  14. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94:3325-3333, 1999
  15. Gianni, AM, Cortelazzo S, Magni M, Martelli, M. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant, 29 Suppl 1:S10-13, 2002 https://doi.org/10.1038/sj.bmt.1703296
  16. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23:2240-2247, 2005 https://doi.org/10.1200/JCO.2005.08.012
  17. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn J B, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol, 24:3121-3127, 2006 https://doi.org/10.1200/JCO.2005.05.1003
  18. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103:4416-4423, 2004 https://doi.org/10.1182/blood-2003-10-3411
  19. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer, 104:1661-1667, 2005 https://doi.org/10.1002/cncr.21391
  20. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, Castilla C, Blanco OJ, Caballero D and San Miguel JF. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol, 78:302-305, 2005 https://doi.org/10.1002/ajh.20283
  21. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol, 6:255-266, 2005 https://doi.org/10.1007/s11864-005-0008-z
  22. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol, 6:394-403, 2006 https://doi.org/10.1038/nri1838
  23. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum, 54:1390-1400, 2006 https://doi.org/10.1002/art.21778
  24. Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez- Larran A, Rodriguez L, Casado M, Gallur L, Giraldo P, Hernandez R, Menor D, Rodriguez MJ, Caballero D, Gonzalez R, Mayans J, Millan I, Cabrera JR. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol, 85:400-406, 2006 https://doi.org/10.1007/s00277-005-0073-1